Elanco Animal Health Incorporated (ELAN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Elanco Animal Health Incorporated (ELAN) Healthcare & Pipeline Overview

Elanco Animal Health Incorporated specializes in developing and marketing a diverse portfolio of health products for pets and farm animals, positioning itself as a key player in the global animal health market with innovative solutions that address various health needs.

What Is the Investment Thesis for ELAN?

Elanco Animal Health Incorporated operates in a robust market characterized by increasing demand for animal health products, driven by rising pet ownership and the need for sustainable livestock production. The company has a market capitalization of $11.4B and a gross margin of 49.4%, indicating strong operational efficiency. Key growth catalysts include an expanding product portfolio, strategic partnerships, and a focus on innovation in therapeutic areas. The company's commitment to R&D positions it well to capture emerging market opportunities, particularly in the pet health segment, which is projected to grow significantly in the coming years. However, potential risks include market competition and regulatory challenges that could impact product development timelines and market entry strategies. Investors should monitor these dynamics as they assess Elanco's future performance.

Based on FMP financials and quantitative analysis

ELAN Key Highlights

Market cap of $11.4B reflects strong market presence in the animal health sector.

• Gross margin of 49.4% indicates operational efficiency compared to industry peers.
• Employee base of 9,000 supports extensive product development and market reach.
• Negative profit margin of -4.9% highlights ongoing challenges in profitability.
• No dividend yield suggests a focus on reinvestment for growth rather than returning capital to shareholders.

Who Are ELAN's Competitors?

ELAN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ELAN's Key Strengths?

Established reputation in the animal health industry with a history dating back to 1954.

• Diverse product offerings addressing a wide range of health needs.
• Strong R&D capabilities leading to innovative product development.
• Robust distribution network enhancing market reach.

What Are ELAN's Weaknesses?

Negative profit margin of -4.9% indicating current profitability challenges.

• Dependence on a few key product lines for a significant portion of revenue.
• Limited presence in certain emerging markets compared to competitors.
• Potential regulatory hurdles impacting product development timelines.

What Could Drive ELAN Stock Higher?

Launch of new therapeutic products targeting pain management in pets expected in Q4 2026.

• Expansion into emerging markets, particularly in Asia and Latin America, is actively underway.
• Continuous investment in R&D to drive innovation and product development across the portfolio.
• Anticipated regulatory approvals for new vaccines and antibiotics in the livestock segment.
• Strengthening partnerships with veterinarians and distributors to enhance market reach.

What Are the Key Risks for ELAN?

Financial-distress signal — its Altman Z-Score of 1.34 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-3.8%) — the business is not currently generating profit on shareholder capital.
• Increased competition from generic alternatives as patents expire.
• Regulatory challenges that may impact product development and market entry.
• Economic fluctuations affecting consumer spending on pet health products.
• Supply chain disruptions impacting product availability and distribution.

What Are the Growth Opportunities for ELAN?

• Expansion in Pet Health: The global pet care market is projected to grow at a CAGR of 6.2% from 2021 to 2028, driven by increasing pet ownership and spending on pet health products. Elanco's innovative offerings in pet therapeutics and preventive care position it to capture a significant share of this expanding market.
• Innovative Product Development: Elanco's investment in R&D is expected to yield new products targeting unmet needs in animal health, particularly in therapeutic areas such as pain management and infectious diseases. This focus on innovation could enhance its competitive edge and drive revenue growth over the next five years.
• Geographic Expansion: Elanco aims to penetrate emerging markets in Asia and Latin America, where demand for animal health products is rising due to increasing livestock production and growing pet ownership. This expansion could significantly enhance revenue streams and market share in these regions over the next decade.
• Sustainability Initiatives: With a growing emphasis on sustainable agricultural practices, Elanco's nutritional health products that enhance livestock productivity while minimizing environmental impact could attract new customers and partnerships, aligning with global sustainability goals.
• Strategic Partnerships: Collaborations with veterinary practices and agricultural organizations can enhance Elanco's distribution channels and market reach. These partnerships are expected to facilitate the introduction of new products and services, driving growth in both pet and livestock segments.

What Threats Does ELAN Face?

• Intense competition from established and emerging players in the animal health sector.
• Regulatory changes that could affect product approvals and market access.
• Economic downturns impacting consumer spending on pet health products.
• Patent expirations leading to increased competition from generic alternatives.

What Are ELAN's Competitive Advantages?

• Strong brand recognition with established product lines in the animal health market.
• Robust R&D capabilities leading to continuous product innovation.
• Diverse product portfolio catering to both companion animals and livestock.
• Extensive distribution network through partnerships with veterinarians and distributors.
• Commitment to sustainability and animal welfare enhances brand loyalty.

What Does ELAN Do?

Elanco Animal Health Incorporated, established in 1954, is headquartered in Greenfield, Indiana, and has grown to become a prominent player in the animal health sector. The company focuses on innovating, developing, manufacturing, and marketing a wide range of products designed for both pets and farm animals. Elanco's product offerings include disease prevention solutions such as parasiticides and vaccines that protect pets from common ailments like worms, fleas, and ticks, marketed under well-known brands like Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco provides therapeutic solutions for pain management, osteoarthritis, ear infections, and other health issues in canines and felines through brands like Galliprant and Claro. For livestock, Elanco's portfolio encompasses vaccines, antibiotics, and nutritional health products including enzymes, probiotics, and prebiotics, catering to poultry, aquaculture, ruminants, and swine production through brands such as Rumensin and Baytril. The company sells its products through a network of third-party distributors, veterinarians, and directly to farm animal producers, including beef and dairy farmers as well as pork, poultry, and aquaculture operations. With approximately 9,000 employees, Elanco is committed to improving animal health and well-being, thereby enhancing food safety and quality worldwide.

What Products and Services Does ELAN Offer?

• Develops and markets health products for pets and farm animals.
• Offers a range of parasiticides and vaccines for disease prevention in pets.
• Provides therapeutic solutions for various health issues in canines and felines.
• Supplies vaccines, antibiotics, and nutritional products for livestock production.
• Sells products through third-party distributors and directly to veterinarians.
• Focuses on innovation and research to enhance animal health and well-being.

How Does ELAN Make Money?

• Generates revenue through the sale of animal health products for pets and livestock.
• Utilizes a diverse product portfolio to address various health needs in animals.
• Partners with veterinarians and distributors to reach end customers effectively.
• Invests in research and development to innovate and expand product offerings.
• Focuses on both preventive and therapeutic solutions to capture a broad market.

What Industry Does ELAN Operate In?

The animal health industry is experiencing robust growth, driven by increasing pet ownership and a heightened focus on livestock health and productivity. Elanco competes with major players such as Revolution Medicines, Inc. (RVMD), Viatris Inc. (VTRS), Neurocrine Biosciences, Inc. (NBIX), Align Technology, Inc. (ALGN), and Dr. Reddy's Laboratories Limited (RDY), each offering specialized products and services. Elanco's diverse product portfolio and commitment to innovation position it favorably within this competitive landscape.

Who Are ELAN's Key Customers?

• Pet owners seeking health products for their dogs and cats.
• Veterinarians who prescribe and recommend animal health solutions.
• Farm animal producers, including beef and dairy farmers.
• Pork and poultry operations looking for health and nutritional products.
• Aquaculture operations requiring specialized health solutions.

Company Profile

Elanco Animal Health Incorporated operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Indianapolis, US. The company is led by CEO Jeffrey N. Simmons. ELAN has traded publicly since 2018.

Elanco Animal Health Incorporated Financial Trajectory

Elanco Animal Health Incorporated (ELAN) reported $1.37B in revenue for Q2 FY2026, a decline of 0.2% compared to the prior quarter. The company recorded net income of $54.0M, with diluted EPS of $0.11. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, ELAN averaged $-0.10 in diluted EPS.

How Elanco Animal Health Incorporated Is Valued

Elanco Animal Health Incorporated carries a market capitalization of $11.4B, placing it in the large-cap category. Analyst price targets span from $26.00 to $30.00, with a consensus of $28.00. At the current price of $22.86, that implies approximately 22% upside potential. Relative to its peer group, ELAN's quantitative score of 33/100 is below the peer average of 63/100.

Return on equity for Elanco Animal Health Incorporated stands at -3.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.5%, showing how much profit it generates from its asset base. ELAN trades at a trailing price-to-earnings ratio of 20.15, roughly in line with the Healthcare sector average of ~21.50x. A current ratio of 2.16 indicates the company holds enough short-term assets to cover its near-term obligations.

Elanco Animal Health Incorporated's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.34 places it in the distress zone, a signal of elevated financial risk.

Elanco Animal Health Incorporated has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 18.9% above estimates on average.

Over the past six months, Elanco Animal Health Incorporated insiders filed 67 SEC Form 4 transactions — 2 sales and 65 purchases. On net that is roughly 252K shares acquired (about $1.4M) — insiders putting money in tends to read as conviction.

ELAN Financials

ELAN Latest News

ELAN Analyst Consensus

ELAN MoonshotScore

Common Questions About ELAN (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources